It inhibits the release of TNF-alpha, IL-6, and other pro-inflammatory cytokines
Combination Therapies : in addition to dual or triple GLP-1R agonist therapy and GLP-1R agonist and gastrointestinal peptide (GIP) therapy [165, 166], nterest has emerged in the combined use of cagrilintidea long-acting amylin analogue that, as monotherapy, produces clinically meaningful weight loss and is well toleratedwith a GLP-1R agonist
These mechanisms make GLP-1 crucial for both glucose control and appetite regulation, making it a key target for therapeutic interventions in diabetes and obesity
Human pilot evidence Three small pilots: a 12-patient knee-pain case series (Lee & Padgett, Alternative Therapies in Health and Medicine, 2021)
Semaglutide has not been shown to cause kidney damage or kidney disease in clinical studies
Although this has several advantages, it requires administration in primary care centers and long dosing intervals